Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  2007-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/NDT/GFM133PMID 17395652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The natural history of chronic allograft nephropathy.

  2005cited by this paper
• Calcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P‐glycoprotein

  2005influential reference
• Age-Related Differences in CYP3A Expression and Activity in the Rat Liver, Intestine, and Kidney

  2004cited by this paper
• Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

  2004cited by this paper
• Characterization of hepatic cytochrome P4503A activity in patients with end‐stage renal disease

  2003cited by this paper
• Cyclosporine A in treatment of membranous lupus nephropathy.

  2003cited by this paper
• Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.

  2003cited by this paper
• Cyclosporine nephrotoxicity.

  2003cited by this paper
• Cytochrome P4502C9 activity in end‐stage renal disease

  2003cited by this paper
• Attenuation of Cyclosporine-Induced Renal Dysfunction by Catechin: Possible Antioxidant Mechanism

  2003cited by this paper
• Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators

  2002cited by this paper
• Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.

  2001influential reference
• Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.

  2001cited by this paper
• P-glycoprotein-mediated drug secretion in mouse proximal tubule perfused in vitro.

  2001cited by this paper
• Decreased in vivo metabolism of drugs in chronic renal failure.

  2000cited by this paper
• Cytochrome P450 CYP3A in human renal cell cancer

  1999cited by this paper
• A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

  1999cited by this paper
• P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney.

  1998cited by this paper
• Bimodal distribution of renal cytochrome P450 3A activity in humans.

  1996cited by this paper
• Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

  1995cited by this paper
• Time course of the decline in renal function in cyclosporine-treated heart transplant recipients.

  1994cited by this paper
• Human P-glycoprotein transports cyclosporin A and FK506.

  1993cited by this paper
• Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization

  1992influential reference
• Expression of cytochrome P450 3A in amphibian, rat, and human kidney.

  1992cited by this paper
• Kidney biopsy findings in cyclosporine-treated patients with insulin-dependent diabetes mellitus

  1991cited by this paper
• Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients.

  1991cited by this paper
• Recent Advances in Cyclosporine Pharmacokinetics

  1991cited by this paper
• Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).

  1990cited by this paper
• Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants.

  1988cited by this paper
• Histopathology of cyclosporine nephrotoxicity.

  1988cited by this paper
• Cyclosporine nephrotoxicity.

  1985cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Ongoing and Novel Challenges in Kidney Transplantation: Therapeutic Approaches to Non-Immunological Risk Factors for Allograft Loss.

  2026cites this paper
• The tradeoff between the efficacy of calcineurin inhibitors: prevention of allograft rejection vs. post-transplant renal and cardiovascular complications

  2025cites this paper
• Tacrolimus toxicity in kidney transplant recipient after wedge liver resection: A case report and review of literature

  2025cites this paper
• Tacrolimus—why pharmacokinetics matter in the clinic

  2023cites this paper
• Perfusion-Dependent Focal Neurologic Deficits in a Critically Ill Heart Transplant Recipient: A Case of Tacrolimus-Associated Reversible Cerebral Vasospasm Syndrome?

  2023cites this paper
• Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients-Preliminary Report.

  2022cites this paper
• The Use of Machine Learning Algorithms and the Mass Spectrometry Lipidomic Profile of Serum for the Evaluation of Tacrolimus Exposure and Toxicity in Kidney Transplant Recipients

  2022cites this paper
• Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients

  2022cites this paper
• RECORDS OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES Mechanisms of Cyclosporin A Induced Hepatotoxicity

  2022cites this paper
• Hypertension in kidney transplant recipients

  2022cites this paper
• New onset hypertension after transplantation

  2022cites this paper
• Etiological and Clinical Evaluations of Patients with Acute Allograft Dysfunction Within the First Year Address

  2021cites this paper
• Frequency of ABCB1 C3435T and CYP3A5*3 Genetic Polymorphisms in the Lebanese Population.

  2021cites this paper
• Role of hypertension in kidney transplant recipients

  2021cites this paper
• Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States

  2020cites this paper
• Identification of Novel Biomarkers for Predicting Kidney Injury Due to Drugs Using “Omic” Strategies

  2020cites this paper
• Identification of Novel Biomarkers for Predicting Kidney Injury Due to Drugs Using “Omic” Strategies

  2020cites this paper
• Profiling of Drug-Metabolizing Enzymes and Transporters in Human Tissue Biopsy Samples: A Review of the Literature

  2019cites this paper
• Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis

  2018cites this paper
• Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis

  2018cites this paper
• Hypertension guidelines: How do they apply to kidney transplant recipients.

  2018cites this paper
• The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity

  2018cites this paper
• CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.

  2018cites this paper
• Targeted metabolomic analysis of 33 amino acids and biogenic amines in human urine by ion-pairing HPLC-MS/MS: Biomarkers for tacrolimus nephrotoxicity after renal transplantation.

  2018cites this paper
• Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis chronic lesions. 4–6 Surveillance of posttransplantation CNI nephrotoxicity Available diagnostic methods

  2018cites this paper
• Influence of tacrolimus metabolism rate on renal function after solid organ transplantation

  2017cites this paper
• Optimalisering av Western blot-metoder for semikvantifisering av CYP3A-enzymer og P-glykoprotein i humant nyrevev

  2017cites this paper
• High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury

  2017cites this paper
• Recovery of CYP3A Phenotype after Kidney Transplantation

  2017cites this paper
• Medication-Induced Nephrotoxicity in Older Patients.

  2016cites this paper
• Unique Considerations When Managing Hypertension in the Transplant Patient.

  2016cites this paper
• Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.

  2016cites this paper
• Role of Pharmacogenomics in Kidney Disease and Injury.

  2016cites this paper
• Optimizing immunosuppressive therapy after renal transplantation

  2015cites this paper
• Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients

  2015cites this paper
• Assessment and management of hypertension in transplant patients.

  2015cites this paper
• Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation

  2015cites this paper
• Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation

  2015cites this paper
• Facteurs de risque d’insuffisance rénale chronique chez les greffés cardiaques : du phénotype aux tests pharmacogénomiques

  2015cites this paper
• Development and validation of a rapid and reliable real-time PCR method for CYP3A5 genotyping.

  2015cites this paper
• Université de Montréal-Thèse numérique

  2014cites this paper
• The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients.

  2014cites this paper
• The Tacrolimus Metabolism Rate Influences Renal Function after Kidney Transplantation

  2014cites this paper
• Clinical and genetic determinants of tacrolimus pharmacokinetics and pharmacodynamics in the transplant population

  2014cites this paper
• Déterminants moléculaires de la néphrotoxicité induite par le tacrolimus après transplantation rénale

  2014cites this paper
• The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation

  2014cites this paper
• Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients.

  2014cites this paper
• Donor Genotype and Intragraft Expression of CYP3A5 Reflect the Response to Steroid Treatment During Acute Renal Allograft Rejection

  2014cites this paper
• Renal drug metabolism in humans: the potential for drug–endobiotic interactions involving cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT)

  2013cites this paper
• Hypertension after Kidney Transplantation: A Pathophysiologic Approach

  2013cites this paper
• Posttransplant hypertension: multipathogenic disease process.

  2013cites this paper
• Calcineurin Inhibitor Nephrotoxicity: A Review and Perspective of the Evidence

  2013cites this paper
• Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

  2013cites this paper
• Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms

  2013cites this paper
• Pregnane X Receptor and Yin Yang 1 Contribute to the Differential Tissue Expression and Induction of CYP3A5 and CYP3A4

  2012cites this paper
• The Impact of CYP3A5 Variation and Pregnancy on the Metabolic Disposition of Calcineurin Inhibitors

  2012cites this paper
• Recent Updates and Potential Clinical Applications

  2012cites this paper
• Genetic and Clinical Determinants of Early, Acute Calcineurin Inhibitor-Related Nephrotoxicity: Results From a Kidney Transplant Consortium

  2012cites this paper
• Donor ABCB1 variant associates with increased risk for kidney allograft failure.

  2012cites this paper
• Pharmacogenetic biomarkers: cytochrome P450 3A5.

  2012cites this paper
• CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele

  2012cites this paper
• Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation.

  2012cites this paper
• The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation

  2012cites this paper
• Pharmacogenetics in Kidney Transplantation

  2012cites this paper
• Cyclosporine: A Review

  2012cites this paper
• CYP 3 A 5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP 3 A 5 in the Proximal Tubule in Carriers of the CYP 3 A 5 * 1 Allele □

  2012influential citation
• Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors.

  2011cites this paper
• Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant

  2011cites this paper
• Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity

  2011cites this paper
• Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus, Mycophenolate Mofetil and Corticosteroids)

  2011cites this paper
• Update on the clinical pharmacogenomics of organ transplantation.

  2010cites this paper
• Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II

  2010cites this paper
• Personalized immunosuppressive therapy in pediatric heart transplantation: Progress, pitfalls and promises.

  2010cites this paper
• Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients

  2010influential citation
• The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity

  2010cites this paper
• Calcineurin inhibitor nephrotoxicity.

  2009cites this paper
• Identification de marqueurs phénotypiques et génétiques influençant la réponse au traitement et le pronostic des patients atteints d'insuffisance cardiaque

  2009cites this paper
• Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients

  2008cites this paper
• Individualizing Therapy in Patients With Chronic Kidney Disease

  2008cites this paper
• Role of Pharmacogenetics of Immunosuppressive Drugs in Organ Transplantation

  2008cites this paper
• CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients

  2008cites this paper
• A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine.

  2008cites this paper
• Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

  2007cites this paper
• Physiologic effects of cytochrome P450 3A activity

  2007cites this paper
• World Journal of Nephrology

  year unknowncites this paper